Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
Our latest work in the life sciences and high-tech fields.
Our work
6 Dimensions Capital
VC InvestmentsEquity investments in multiple portfolio companies, including Hibercell
Website
Puma Biotechnology, Inc.
Clinical TrialCRO and Site Agreements for an Open-Label, Phase 2 Study with 30 Sites in 9 Countries exploring the efficiency of Neratinib on Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations Or EGFR Gene Amplification
See Study
Vizgen, Inc.
Series C FinancingVizgen raises Series C equity funding led by Blue Water Life Science Advisors, LLC, ARCH Venture Fund X, L.P. and other existing investors
Press Release
Vernal Biosciences, Inc.
Series A FinancingVernal Biosciences raises $21M Series A equity funding led by Dynamk Life Sciences Fund, L.P., Charles River Laboratories, Inc. and Ampersand 2020 Limited Partnership
Press Release
Artax Biopharma, Inc. + Advent Life Sciences Fund II LP
Series B Financing (Series B4)Artax Biopharma raises Series B-4 round of equity funding led by Advent Life Sciences Fund II LP, Advent Life Sciences LLP, Columbus Life Science Fund II, FCR, Hiyuli Ventures Limited, Belinda A. Termeer, and other existing investors, plus new investors including Sound Bioventures Fund I AB and and Eli Lilly
Press Release
Dianthus Therapeutics, Inc.
Series A FinancingDianthis raises $100 million Series A financing led by 5AM Ventures, Fidelity Management & Research Company, Avidity Partners, Venrock, Fairmount Funds, Tellus BioVentures and other investors
Press Release
Summation Bio, Inc.
Series A FinancingSummation Bio raises Series A equity funding led by RA Capital Healthcare Fund, L.P., RA Capital NEXUS Fund, L.P., RA Capital NEXUS Fund III, L.P., Blackwell Partners LLC and other existing investors
ONK Therapeutics Limited + Intellia Therapeutics, Inc.
License, Collaboration and Option AgreementLicense, Collaboration and Option Agreement to advance allogeneic CRISPR-Edited NK cell therapies, with milestones up to $920M per product plus royalties
Press Release
DermBiont, Inc. + Chromaderm, Inc.
Private Company AcquisitionDermBiont acquires Chromaderm, Inc.
Press Release
Sirtex Technology Pty Ltd
Clinical TrialCRO and Site Agreements for a pivotal device study with 15 US sites to evaluate the safety and effectiveness of SIRT using SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC (Barcelona clinic liver cancer (BCLC) stage A, BCLC stage B1 and BCLC stage B2)
See Study
IDEAYA Biosciences, Inc.
Clinical TrialCRO and Site Agreements for a Phase I Study to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses of IDE397 (MAT2A inhibitor) in patients with advanced solid tumors
See Study
Vizgen, Inc.
Series B FinancingVizgen raises Series B equity funding from Northpond Ventures LP, ARCH Venture Fund X, L.P., Novalis LifeSciences LLC, Tao Capital Management, Pura Vida Investments and other current investors
Press Release
5AM Venture Management LLC + Entrada Therapeutics, Inc.
Series B FinancingNeed to remove?
Press Release
Global Alliance for TB Drug Development + GlaxoSmithKline
Research and Development Collaboration AgreementAmended and Restatement of Research and Development Collaboration Agreement with GSK to identify and advance novel chemical entities for the potential treatment of TB as well as non-tuberculosis mycobacterial infections
Press Release
FOG Pharmaceuticals, Inc.
Series C Preferred FinancingFogPharma raises Series C equity funding led by venBio Partners, Cormorant Asset Management, Farallon Capital Mgmt., Invus, funds/accounts advised by T. Rowe Price, HBM Healthcare Investments, Casdin Capital and PagsGroup, w/participation from investors GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital
Press Release
GV Management Company, LLC + Hyperfine Research
Series D FinancingFaber has assisted GV in Hyperfine Research’s $90M Series D Financing
Press Release